[ET Net News Agency, 2 August 2021] Luye Pharma Group Ltd. (02186) said the group has
submitted the investigational new drug (IND) application for its new central nervous
system (CNS) drug LY03015 to the Food and Drug Administration (FDA) of the U.S.
LY03015 is an innovative small molecule compound product indicated for the treatment of
tardive dyskinesia and Huntington's disease, developed by the group. (RC)